Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
411.044439726
InChI
InChI=1S/C20H14ClN3O3S/c21-14-7-3-2-6-13(14)15-11-28-20(22-15)23-19(27)17-9-12-5-1-4-8-16(12)24(17)10-18(25)26/h1-9,11H,10H2,(H,25,26)(H,22,23,27)
InChI Key
InChIKey=ILNRQFBVVQUOLP-UHFFFAOYSA-N
IUPAC Name
2-(2-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl}-1H-indol-1-yl)acetic acid
Traditional IUPAC Name
(2-{[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl}indol-1-yl)acetic acid
SMILES
OC(=O)CN1C(=CC2=CC=CC=C12)C(=O)NC1=NC(=CS1)C1=CC=CC=C1Cl
pKa (strongest acidic)
4.19
pKa (Strongest Basic)
-1.2
Refractivity
107.79 m3·mol-1
Dược Lực Học :
Lintitript SR 27897 is a selective cholecystokinin type A (CCK-A) receptor antagonist. In February 2000, Sanofi announced that it was halting development of the drug for appetite disorders, and in September 2002, Sanofi announced that it had stopped investigation all together.
Cơ Chế Tác Dụng :
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
Chỉ Định :
For the treatment of pancreatic cancer and appetite disorders.